Allergen immunotherapy: 100 years, but it does not look like

European Annals of Allergy and Clinical Immunology

Volumn 44, Issue 3, 2012, Pages 99-106

  Frati, F ^a   Incorvaia, C ^b   Lombardi, C ^c   Senna, G ^d  

^a Medical and Scientific Department   (Italy)

^b ICP Hospital   (Italy)

^c S Orsola Hospital   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

Allergy; Asthma; Efficacy; Rhinitis; Safety; Specific immunotherapy; Venom immunotherapy

Indexed keywords

ADRENALIN; ALLERGEN; ANT VENOM; BEE VENOM; CHLORPHENIRAMINE MALEATE; HYMENOPTERA VENOM; IMMUNOMODULATING AGENT; OMALIZUMAB; PLACEBO; RECOMBINANT ALLERGEN;

ALLERGIC ASTHMA; ALLERGIC REACTION; ALLERGIC RHINITIS; ANAPHYLAXIS; ATOPIC DERMATITIS; BRONCHUS HYPERREACTIVITY; CELL FUNCTION; CLUSTER ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FOOD ALLERGY; HOUSE DUST ALLERGY; HUMAN; INSECT STING; MASTOCYTOSIS; META ANALYSIS; META ANALYSIS (TOPIC); MORTALITY; OBSERVATIONAL STUDY; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; RETROSPECTIVE STUDY; REVIEW; RISK; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TABLET;

CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 84862670386     PISSN: 17641489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Bousquet J, Lockey R, Malling HJ (eds). Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO Position Paper. J Allergy Clin Immunol 1998; 102:558-62.
2. Noon L, Cantab BC, Eng FR. Prophylactic inoculation against hay fever. Lancet 1911;177;1572-3.
3. Frankland A, Augustin R. Prophylaxis of summer hay fever and asthma: a controlled trial comparing crude grass pollen extract with the isolated main protein components. Lancet 1954;266;1055-8.
4. Hunt KJ, ValentineMD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-61.
5. Committee on Safety in Medicine: CSM update: desensitizing vaccines. BMJ 1986; 293;948.
6. Lockey RF, Benedikt LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79; 660-77.
7. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986;6:483-91.
8. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111:437-48.
9. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials Am J Respir Crit CareMed 1995;151:969-74.
10. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003;4: CD001186.
11. Abramson MJ, Puy RM, Weiner JM. Injection immunotherapy for asthma. Cochrane Database Syst Rev 2010;8: CD001186.
12. CalderonMA. Alves B, JacobsonM, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;1: CD001936.
13. Nelson H. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009;123:763-9.
14. Ciprandi G, Alesina R, Ariano R, et al. Characteristics of patients with allergic polysensitization: the POLISMAIL study. Eur Ann Allergy Clin Immunol 2008;40: 77-83.
15. Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and and systemic side-effects during induction treatment. Clin Exp Allergy 2000;30: 1423-29.
16. Serrano P, Justicia JL, Sanchez C, et al. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administred using clustered regimens: a retrospective, observational, mutlicenter study. Ann Allergy Asthma Immunol 2009;102:247-52.
17. Schiappoli M, Ridolo E, Senna G, et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin Exp Allergy 2009;39: 1569-74.
18. Wilson DR, Torres-Lima M, Durham S: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60: 4-12.
19. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol 2005;15:9-16.
20. Penagos M, Passalacqua G, Compalati E, et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133: 599-609.
21. Calamita Z, Saconato H, Pela AB, Atallah AN: Efficacy of sublingual immunotherapy in asthma: systematic review of randomizedclinical trials using the Cochrane Collaboration method. Allergy 2006;61:1162-72.
22. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3-18 years of age: a meta analysis of randomized placebo-controlled, double blind trials. Ann Allergy Asthma Immunol 2006;97:141-8.
23. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;12: CD002893.
24. Di Bona D, Plaia A, Scafidi V, Leto-BaroneMS, Di Lorenzo G: Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010;26: 558-66.
25. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009;64:1570-79.
26. Durham SR, YangWH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once daily grass allergen tablet: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9.
27. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:338-45.
28. Wahn U, Tabar A, Kuna P, et al. SLIT Study Group. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6.
29. Canonica GW, Bousquet J, Casale T, et al (eds). Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64 (suppl 91):1-59.
30. Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005;35:565-71.
31. André C, Fadel R: Anaphylaxis caused by allergen sublingual immunotherapy? Allergy 2007;62:1220-1.
32. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963-4.
33. Cochard MM, Eigenmann PA. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol 2009;124:378-79.
34. Incorvaia C, Mauro M. Do indications to sublingual immunotherapy need to be revised? J Allergy Clin Immunol 2010;125:277-8.
35. Müller U, Thurnheer U, Patrizzi R, Spiess J, Hoigné R. Immunotherapy in bee sting hypersensitivity. Bee venom versus whole body extract. Allergy 1979;34:369-78.
36. Brown SG, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003;361:1001-6.
37. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 2000;22:351-8.
38. Müller U, Helbling A, Berchtold E. Imunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-35.
39. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027-32.
40. Incorvaia C, Frati F, Dell'Albani I, et al. Safety of hymenoptera venom immunotherapy: a systematic review. Exp Opin Pharmacother 2011; Epub Ahead of print.
41. Bilò BM, Bonifazi F. Hymenoptera venom immunotherapy. Immunotherapy 2011;3:229-46.
42. Ruëff F, Przybilla B, Bilò MB, et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of basseline serum tryptase. J Allergy Clin Immunol 2010;126:105-11.
43. Dugas-Breit S, Przybilla B, Dugas M, et al. Serum concentration of baseline mast cell tryptase: evidence for a decline during longterm immunotherapy for Hymenoptera venom allergy. Clin Exp Allergy 2010;40:643-649.
44. Bonadonna P, Zanotti R, Müller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010;10:347-53.
45. Lerch E, Müller U. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-12.
46. Golden DBK. Discontinuing venom immunotherapy. Curr Opin Allergy Clin Immunol 2001;1:353-6.
47. Hafner T, DuBuske L, Kosnik M. Long term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol 2008;100:162-5.
48. Oude Elberink JN, De Monchy JGR, Kors JW, et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99:153-4.
49. Durham SR, Leung DYM. One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol 2011;127:3-7.
50. Bousquet J, Van Cauwenberge P, Khaltaev N; ARIA Workshop group;World Health Organization. Allergic Rhinitis and its Impact on Asthma. J Allergy Clin Immunol 2001;108(5 Suppl): S147-334.
51. Bousquet J, Khaltaev N, Cruz AA (Eds). Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy, 2008, 63(Suppl. 86):8-160.
52. NHLBI/WHO Workshop report. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. January 1995, NIH Publication No. 02-3659.
53. http://www.ginasthma.com
54. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951-60.
55. Drachenberg HJ, Wheeler H. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56:498-505.
56. Passalacqua G, Lombardi C, Troise C, Canonica GW. Sublingual immunotherapy: certainties, unmet needs and future directions. Eur Ann Allergy Clin Immunol 2009; 41:163-70.
57. Nagata M, Nakagome K. Allergen immunotherapy in asthma: current status and future perspectives. Allergol Int 2010;59:15-9.
58. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992; 90:256-62.
59. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebocontrolled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005;116:1073-9.
60. Fernandez-Rivas M, Garrido FS, Nadal JA, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p3 quantified peach extract. Allergy 2009;64:876-83.
61. Kurihara K. Immunotherapy for food allergy. Allergol Int 2010;59:9-14.
62. Leynadier F, Herman D, Vervloet D, Andrè C. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000;106:585-90.
63. Rolland JM, Drew AC, O'Hehir RE. Advances in development of hypoallergenic latex immunotherapy. Curr Opin Allergy Clin Immunol 2005;5:544-51.
64. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol, 2007;7:542-6.
65. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105:17908-12.
66. Martinez-Gomez JM, Johansen P, Erdman I, et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009;50:59-65.
67. Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124:997-1002.